A Study With LY293111, Gemcitabine and Placebo in Patients With Pancreatic Cancer

Phase 2

Completed

• Conditions: Pancreatic Cancer

• Registration Number: NCT00055250
• Lead Sponsor: Eli Lilly and Company

Brief Summary

The purpose of this study is to determine the effectiveness and side effects of LY293111 given in combination with gemcitabine in patients with pancreatic cancer.

Detailed Description

Not available

Study Timeline

• Study Start: 2003-01
• Study First Submitted: 2003-02-21
• Study First Submitted QC: 2003-02-21
• Study First Posted: 2003-02-24
• Study Completion: 2005-10
• Status Verified: 2007-01
• Last Update Submitted: 2007-01-24
• Last Update Posted: 2007-01-26

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 130

Inclusion Criteria

• Adenocarcinoma of the pancreas that is locally advanced or metastatic and not amenable to resection with curative intent
• Tumor that can be measured by x-ray or scan
• Adequate organ function

Exclusion Criteria

• Inability to swallow capsules
• Documented brain metastases
• Prior chemotherapy or biological therapy for this disease

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
6-month survival

Secondary Outcome Measures

Name	Time	Method
Toxicity
tumor response
PK

Trial Locations

Locations (1)

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5pm Eastern time (UTC/GMT - 5 hours, EST) or speak with your personal physician.; 🇺🇸 Lakeland, Florida, United States